Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Human Papillomavirus Vaccine
65%
HPV16
57%
Community-randomized Trials
25%
Finland
25%
Vaccination Strategy
21%
Vaccine Effectiveness
19%
Quality of Life
19%
Population-based
19%
Preterm Birth Rate
19%
Registry-based
19%
Vaccine Registry
19%
C.trachomatis
19%
Adolescent Women
19%
Chlamydia Trachomatis Infection
19%
Cervical Atypia
19%
Oral Contraceptives
19%
Squamous Intraepithelial Lesion
19%
Cluster Randomized Trial
19%
Cancer Population
19%
Randomized Clinical Trial
19%
Cervical Cancer Screening
18%
Hepatitis B Vaccine
18%
AS04
18%
Vaccination
17%
Overall Effectiveness
16%
Birth Cohort
12%
Trial Registration
12%
Herd Effect
9%
Total Effectiveness
9%
Cancer Cases
8%
Cervical Cancer
8%
Joint Effect
7%
RAND-36
7%
Duration of Infection
7%
Oral Contraceptive Use
7%
Role Functioning
7%
EQ-VAS
7%
Unvaccinated
7%
Human Papillomavirus Types
7%
Gender Neutral
6%
Older Women
6%
Clinical Trials
5%
Medicine and Dentistry
Wart Virus
96%
Human Papillomavirus Type 16
30%
Arm
29%
Adolescence
21%
Premature Labor
19%
Vaccine
19%
Cluster Randomized Trial
19%
Quality of Life
19%
Birth Rate
19%
Malignant Neoplasm
19%
Chlamydia Infection
19%
Oral Contraceptive
19%
Randomized Clinical Trial
19%
AS04
14%
Oral Contraceptive Use
12%
Cervical Cancer Screening
12%
Hepatitis B Vaccine
10%
Cytotechnology
9%
Infection
8%
Herd
6%
Disease
6%
Condom Use
6%
Logistic Regression Analysis
6%
Cervical Cancer
5%
